Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.
Infect Immun. 2012 Apr;80(4):1554-62. doi: 10.1128/IAI.06388-11. Epub 2012 Feb 6.
Escherichia coli sequence type ST131 (O25b:H4) has emerged over the past decade as a globally disseminated, multidrug-resistant pathogen. Unlike traditional antimicrobial-resistant E. coli, ST131 derives from virulence-associated phylogenetic group B2 and exhibits extraintestinal virulence factors. This, plus preliminary evidence of virulence in experimental animals, has suggested that ST131's epidemic emergence may be due to high virulence potential, compared with other E. coli types. To test this hypothesis, we compared a large number of matched ST131 and non-ST131 E. coli clinical isolates, both fluoroquinolone resistant and susceptible, plus isolates from classic extraintestinal pathogenic E. coli (ExPEC) sequence types (STs) and case report ST131 household transmission isolates, for virulence in a mouse subcutaneous sepsis model. Overall, in mice, the study isolates produced a wide range of lethality and clinical illness. However, neither ST131 status nor fluoroquinolone phenotype correlated with this diversity of illness severity, which occurred within each of the 6 study groups. In contrast, multiple known or suspected ExPEC virulence genes, including pap (P fimbriae), vat (vacuolating toxin), kpsM II (group 2 capsule), ibeA (invasion of brain endothelium), and clbB/N (colibactin synthesis), plus molecularly defined ExPEC status, were significantly associated with virulence. These findings point away from ST131 isolates as having higher virulence potential compared with other E. coli types in causing invasive extraintestinal infections and suggest instead that ST131's epidemiological success may reflect enhanced fitness for upstream steps in pathogenesis or in colonization and transmission. Additionally, the extensive within-ST virulence diversity suggests an opportunity to compare closely related strains to identify the responsible genetic determinants.
大肠埃希氏菌序列型 ST131(O25b:H4)在过去十年中作为一种全球传播的、多药耐药病原体出现。与传统的抗微生物耐药大肠埃希氏菌不同,ST131 源自与毒力相关的进化群 B2,并具有肠外毒力因子。这一点,加上实验动物中初步的毒力证据,表明 ST131 的流行出现可能是由于其高毒力潜力,与其他大肠埃希氏菌类型相比。为了验证这一假设,我们比较了大量匹配的 ST131 和非 ST131 大肠埃希氏菌临床分离株,包括氟喹诺酮耐药和敏感的分离株,以及来自经典肠外致病性大肠埃希氏菌(ExPEC)序列型(ST)和病例报告 ST131 家庭传播分离株的分离株,以评估其在小鼠皮下脓毒症模型中的毒力。总体而言,在小鼠中,研究分离株产生了广泛的致死率和临床疾病。然而,ST131 状态或氟喹诺酮表型均与这种疾病严重程度的多样性无关,这种多样性发生在 6 个研究组中的每一个。相比之下,多个已知或可疑的 ExPEC 毒力基因,包括 pap(P 菌毛)、vat(空泡毒素)、kpsM II(群 2 荚膜)、ibeA(脑内皮细胞侵袭)和 clbB/N(colibactin 合成),加上分子定义的 ExPEC 状态,与毒力显著相关。这些发现表明,与其他大肠埃希氏菌类型相比,ST131 分离株在引起侵袭性肠外感染方面的毒力潜力并没有更高,这表明 ST131 的流行病学成功可能反映了其在发病机制的上游步骤或在定植和传播方面的适应性增强。此外,ST 内广泛的毒力多样性表明有机会比较密切相关的菌株,以确定负责的遗传决定因素。